Freenome, Inc. Company Profile

03:03 EST 12th December 2018 | BioPortfolio

Freenome is an AI genomics company on a mission to empower everyone with the tools they need to detect, treat, and ultimately prevent their diseases. By applying advanced machine learning techniques to recent breakthroughs in genomic science, Freenome is developing noninvasive blood tests to detect early-stage cancer and improve precision oncology treatments for millions of patients. The company has raised $78 million from investors such as Andreessen Horowitz, Google Ventures, Polaris Partners, and Founders Fund. More information at:

News Articles [5 Associated News Articles listed on BioPortfolio]

Qiagen teams up with Freenome on companion Dx development

Qiagen and Freenome will collaborate on the development of next-generation sequencing-based companion diagnostics for immuno- -More- 

Freenome’s IMPACT Advisory Board Brings Strategic Insight and Real-World Experience to AI-Genomics Cancer Tests

Freenome, a leading artificial intelligence (AI) genomics company, announced the creation of its IMPACT Advisory Board, a group tasked with helping Freenome’s leadership ...

QIAGEN showcases innovation in NGS solutions for precision medicine at ASCO 2018

Introduces pipeline to reach patients more quickly with next-generation sequencing for cancer, in line with modernized regulatory approach from the U.S. Food and Drug...

Freenome Unveils Promising Early Data on Colorectal Cancer Screening Test at American College of Gastroenterology Annual Meeting

South San Francisco–based Freenome, the leading artificial intelligence (AI) genomics company, is presenting promising early data on its efforts to utilize machine learning to d...

Christian Doppler Research Grant Awarded to Freenome and the Medical University of Graz to Advance Understanding of Gene Expression Changes in Cancer Using Circulating Biomarkers

Freenome and the Medical University of Graz jointly announced the launch of a new Christian Doppler (CD) Laboratory dedicated to advancing research into early-cancer detect...

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

AI-EMERGE: Development and Validation of a Multi-analyte, Blood-based Colorectal Cancer Screening Test

Freenome is using a type of artificial intelligence, called machine learning, to identify patterns of cell-free biomarkers in blood to detect cancer early. The purpose of this study is to ...

Companies [2 Associated Companies listed on BioPortfolio]


Headquartered in South San Francisco, Freenome is a health technology company developing accurate, accessible and non-invasive disease screening products for proactively treating ...

Freenome, Inc.

Freenome is an AI genomics company on a mission to empower everyone with the tools they need to detect, treat, and ultimately prevent their diseases. By applying advanced machine ...

More Information about "Freenome, Inc." on BioPortfolio

We have published hundreds of Freenome, Inc. news stories on BioPortfolio along with dozens of Freenome, Inc. Clinical Trials and PubMed Articles about Freenome, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Freenome, Inc. Companies in our database. You can also find out about relevant Freenome, Inc. Drugs and Medications on this site too.

Quick Search


Relevant Topic

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Corporate Database Quicklinks

Searches Linking to this Company Record